Hugel Inc., a leading global medical aesthetics company chaired by Suk Cha, has officially launched its botulinum toxin product Letybo in Malaysia – an emerging market for medical aesthetics in Southeast Asia.
The company’s Malaysian partner Venusys Medical Sdn Bhd introduced Letybo at the Aesthetic Medicine & Surgery Conference & Exhibition (AMSC), the largest medical aesthetics conference in Malaysia, held from August 6 to 7.
Konstantin Frank, a key opinion leader for Letybo in Europe, delivered a presentation at the event, highlighting the precise treatment outcomes of botulinum toxin procedures and sharing clinical strategies to enhance procedural results.
A brand launch event and hands-on workshop followed on August 8 at The Zenith Hotel Kuantan, with around 100 local medical professionals in attendance. The workshop served as a training program focused on botulinum toxin injection techniques that integrate anatomical understanding with clinical expertise.
Venusys Medical, headquartered in Malaysia and operating across Malaysia and Singapore, is a distributor of medical aesthetic products and a long-standing partner of various global brands.
“We will continue to offer customized training programs for local medical professionals in Malaysia through our strategic collaboration with Venusys Medical,” a Hugel official said. “We aim to enhance the customer experience of our premium toxin brand and accelerate its market penetration to solidify our position in the region.”
